#China #Shanghai #XPOVIO #Antengene #ATG-022

Antengene's Interim Financial Results Overview

On August 22, 2025, Antengene Corporation Limited, a global biotech firm, disclosed its interim results ending June 30, 2025. The company reported substantial advancements in its clinical pipeline, particularly with their innovative therapeutic platforms. The highlights of the report indicate robust clinical efficacy for several drugs under development, alongside impressive financial growth in revenue.

Key Clinical Achievements

ATG-022: A Potential Breakthrough in Gastric Cancer Treatment

The Phase I/II CLINCH study of ATG-022, an antibody-drug conjugate directed against CLDN18.2, revealed promising clinical efficacy across various levels of CLDN18.2 expression in patients diagnosed with gastric or gastroesophageal junction adenocarcinoma. The data showcased an outstanding objective response rate (ORR) of 40% in moderate-to-high expressors, with a corresponding disease control rate (DCR) of 90%. Furthermore, the dataset included significant progression-free survival rates, depicting the potential of ATG-022 as a cornerstone therapy for gastric cancer.

In recognition of its findings, ATG-022 received the Breakthrough Therapy designation from China's National Medical Products Administration (NMPA), affirming its potential as a vital treatment avenue for patients who have exhausted other therapies.

The focus on enhancing the clinical journey for gastric cancer patients is a priority; thus, Antengene is advancing multiple trials that will evaluate ATG-022 in first, second, and third-line therapy settings.

Promising Developments from ATG-037

The company also reported progress on ATG-037, an oral CD73 small molecule inhibitor currently under evaluation in combination therapies for CPI-resistant melanoma and non-small cell lung cancer (NSCLC). Within the STAMINA study, preliminary data demonstrated striking efficacy, particularly in the melanoma subgroup, with a 36.4% ORR. The findings suggest significant long-term antitumor activity, reinforcing ATG-037's potential to revolutionize treatment strategies in these hard-to-treat cancers.

Expanding Reach: ATG-201 for Autoimmune Diseases

In a strategic expansion, Antengene presented preclinical results for ATG-201, designed for autoimmune conditions. Data from non-human primate models suggest that this target has favorable tolerability and substantially low cytokine release, promoting its expected entrance into clinical studies by Q4 2025.

Financial Performance Metrics

Antengene's financial report revealed a remarkable 70.6% increase in revenue, culminating in RMB 53.2 million in the first half of 2025. This revenue growth correlates with the increased footprint of XPOVIO®, the company’s flagship product, which is now approved for multiple indications across several Asia-Pacific markets. This financial stability is coupled with a significant reduction in expenses, emphasizing operational efficiency.

The availability of RMB 794 million in cash reserves positions Antengene favorably, allowing for sustained funding of their clinical programs, development strategies, and paving the way for future innovations.

Looking Forward

Dr. Jay Mei, Antengene's Founder and CEO, expressed optimism regarding the company's trajectory, emphasizing that the advancements in clinical programs, combined with strong financial metrics, underscore their commitment to transforming patient care through innovative therapies. Antengene aims to expedite the commercialization of its key assets and develop cutting-edge therapies that meet pressing global healthcare needs.

In conclusion, Antengene's interim financial results not only reflect its financial resilience but also its dedication to clinical excellence and patient-centric innovations, making a noticeable impact in the biopharmaceutical landscape.

For detailed insights into the full range of developments and data, refer to Antengene's Investor Relations section on their official website.